Skip to main content

Autonomous Oxygen Titration for Maintaining Normoxemia in Acutely Ill Adults: The SAVE-O2 AI Randomized Clinical Trial

In brief

AI-driven oxygen titration raises time in target range by 21%

In a randomized trial of 300 hospitalized adults needing supplemental oxygen, an autonomous titration system kept patients within the SpO2 goal of 90-96% for 85% of monitoring time versus 63% with usual clinician adjustments, a 21-percentage-point gain. It also cut hypoxemia time modestly and reduced hyperoxemia, suggesting automated control can improve oxygen management, though impact on clinical outcomes remains unknown.

Journal
JAMA internal medicine (Q1)
Published
3 August 2026
Study design
Randomized controlled trial
Evidence level
Level 1, High (CEBM 1b)
Authors
David J Douin, John D Rice, Mengli Xiao, Laurel E Beaty, Claire J Guo, Cori Withers, et al.
PMID
42546017
DOI
10.1001/jamainternmed.2026.4023

Why clinicians should know about it

  • Picked for Emergency Medicine (top studies of the week, 9 August 2026).
  • Picked for Internal Medicine (top studies of the week, 9 August 2026): Autonomous oxygen titration RCT improves normoxemia time

Abstract

IMPORTANCE: For acutely ill adults who are hospitalized with hypoxemia, supplemental oxygen is titrated to maintain normoxemia. In current practice, clinicians intermittently titrate oxygen, potentially exposing patients to hypoxemia and hyperoxemia between assessments. Autonomous oxygen titration may address these challenges by independently titrating supplemental oxygen flow to maintain peripheral oxygen saturation (Spo2) within a predefined range. OBJECTIVE: To determine whether autonomous oxygen titration increases the proportion of time spent in a targeted normoxemia range compared with usual care in acutely ill adults. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, unblinded, parallel-group, randomized clinical trial was conducted at 4 US hospitals from May 6, 2024, to November 17, 2025, among adults hospitalized for acute respiratory illness, trauma, burn, or acute care surgery who were receiving supplemental oxygen. INTERVENTION: Patients were randomly assigned to receive oxygen titration via either autonomous oxygen titration or usual care (manual oxygen titration by clinicians) during the first 72 hours after randomization. MAIN OUTCOMES AND MEASURES: The primary outcome was the proportion of time spent within the targeted normoxemia range (Spo2 90%-96%). The key secondary outcome was the proportion of time spent in hypoxemia (Spo2 <88%). RESULTS: Among 300 patients randomized and included in the trial population (median [IQR] age, 66 (55-75) years; 162 [54%] female), 152 were assigned to autonomous oxygen titration and 148 to usual care. Participants represented a range of skin pigmentation categories defined by the Monk Skin Tone Scale, including 67 (22%) categorized as light, 168 (56%) as medium, and 65 (22%) as dark. The mean (SE) proportion of time spent in normoxemia was greater in the autonomous oxygen titration group than in the usual care group (85% [1%] vs 63% [2%]; adjusted risk difference [RD], 21 percentage points [pp]; 95% CI, 18-25 pp; P < .001). The mean (SE) proportion of time spent in hypoxemia was lower in the autonomous oxygen titration group than in the usual care group (2.0% [0.2%] vs 3.6% [0.4%]; adjusted RD, -1.3 pp; 95% CI, -2.0 to -0.5 pp; P = .002). The mean (SE) proportion of time spent in hyperoxemia (Spo2 >96%) was 9.2% (1.0%) in the autonomous oxygen titration group and 29.1% (1.7%) in the usual care group. The mean (SE) proportion of time spent in borderline hypoxemia (Spo2 88%-89%) was 3.4% (0.3%) in the autonomous oxygen titration group and 4.0% (0.4%) in the usual care group. Results were consistent across prespecified subgroups. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial among adults hospitalized with an acute illness or injury and receiving supplemental oxygen, autonomous oxygen titration substantially increased the proportion of time spent in normoxemia and decreased time spent in hypoxemia compared with usual care. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT06374225.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.